An oral β-3-adrenoreceptor agonist for the treatment of overactive bladder.
Horizon Scanning
It is a challenge for health plans and clinicians to know what emerging technologies are in the preapproval phase and what their clinical, financial, and risk impacts might be. This is where we come in.The Hayes Horizon Scanning Solution identifies innovative and potentially disruptive health technologies that are in various stages of the regulatory approval process. Our Research Analysts continually investigate new technologies that are on the horizon or in the early stages of clinical investigation, as well as the testing of existing technologies that may be seeking approval for new clinical applications. Hayes Horizon Scanning helps you track emerging technologies before you need to make decisions. Accessed through the Hayes Knowledge Center, Hayes Horizon Scanning addresses the following fundamental questions to help our clients forecast emerging technologies:
- Is this emerging technology new or replacing an existing technology?
- Where is this technology in the FDA regulatory process?
- When will this technology be commercially available in the market?
- What is the projected use, cost, and financial impact of this technology?
Belviq® (Lorcaserin)
An oral, selective, 5-HT2C receptor agonist to promote long-term weight management.
MEVION S250™ Proton Therapy System
A single-room proton therapy system with a gantry-mounted superconducting synchrocyclotron intended as an alternative to conventional large proton therapy systems.
Edwards Sapien® Transcatheter Heart Valve
A prosthetic heart valve for transcatheter aortic valve implantation.
PICO™ Negative Pressure Wound Therapy System
A single-use negative pressure wound therapy system for use in the hospital and at home for treatment of a variety of chronic, acute, traumatic, and surgical wounds.
CoreValve® Transcatheter Aortic Valve System
A self-expanding, prosthetic, aortic valve for percutaneous or trans-subclavian implantation, developed as an alternative to current care surgical aortic valve replacement in patients with severe aortic stenosis at a high or prohibitive risk for operative mortality.
Xgeva® (Denosumab) to Delay Onset of Bone Metastasis in Men with Nonmetastatic Castration-Resistant Prostate Cancer
A once-monthly injected biologic agent for prevention of bone metastases in men with nonmetastatic castration-resistant prostate cancer at high risk for rapid progress of disease to the bone.
mySentry™ Remote Glucose Monitor
A separately sold accessory used with the MiniMed Paradigm REAL-Time Revel system for within-the-home remote continuous glucose monitoring.
Antimicrobial Copper™ Surfaces for Infection Control
Copper and copper-based alloys intended to be used instead of existing building materials (e.g., stainless steel) for commonly touched hospital surfaces, such as door handles, bathroom fixtures, and other furnishings, as an antimicrobial measure in conjunction with standard infection control practices.
Cardiac Resynchronization Therapy / Implantable Cardioverter Defibrillator (CRT/ICD), Expanded Indication
Implantable devices that combine cardiac resynchronization therapy and defibrillation to reduce chronic heart failure events in patients with asymptomatic or mild to moderate heart failure (NYHA Class I/II).